Pfizer raises full-year forecast after Q3 results — CNBC
Pfizer raised its full-year revenue forecast to $62B–$64B and adjusted EPS to $2.95–$3.05 after Q3 results beat expectations, with revenue of $16.58B and EPS of 87 cents. The company also appointed Cécile Gégout as CFO.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift suggest stronger demand and cost control, supporting a bullish stance.
Market read
Pfizer's guidance upgrade is a material catalyst for the stock and the healthcare sector.
What to watch
Potential headwinds from generic competition and upcoming patent expiries could temper long‑term upside.
Background
Pfizer reported Q3 adjusted earnings of $0.87 per share versus $0.73 consensus and revenue of $16.58B versus $15.87B forecast.
Ticker impact
Pfizer raised its full-year revenue forecast to $62‑$64B and EPS guidance to $2.95‑$3.05 after Q3 results beat expectations.
likely upward pressure as investors price in higher revenue and earnings.
The raise follows a beat on Q3 earnings, indicating momentum; analysts typically bid the stock on such upgrades.
Market effects
Boosts outlook for the broader pharma sector as a bellwether improves guidance.
U.S. market may see modest gains in healthcare indices.
Limited to investors tracking large‑cap pharma stocks.
Counterpoint
If the guidance upgrade is already priced in, the stock could face a short‑term pull‑back.
Key entities
- personCécile Gégout
New CFO of Pfizer, may influence future financial strategy.
